Drug Type TCR-T Cell therapy |
Synonyms Anti-NY-ESO-1 TCR - T-Cure, 402 TCR |
Target |
Action inhibitors |
Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bladder Cancer | Preclinical | United States | - | |
| Liver Cancer | Preclinical | United States | - | |
| Ovarian Epithelial Carcinoma | Preclinical | United States | - | |
| Sarcoma | Preclinical | United States | - |





